Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at Ga-DOTANOC PET/CT imaging.

Background: Ga-DOTANOC PET/CT is routinely used to image neuroendocrine tumors (NETs). A case of lymphoma initially thought to be NET based on a positive Ga-DOTANOC PET/CT was recently seen at our institution. This prompted us to determine prospectively somatostatin receptor (SSTR) status in patients with lymphoma by immunohistochemical analysis of SSTR subtypes 2, 3 and 5 (SSTR) and Ga-DOTANOC PET/CT imaging.

Material And Methods: Twenty-one patients with newly diagnosed lymphoma were referred to Ga-DOTANOC and FDG PET/CT prior to any treatment. Tracer uptake was evaluated visually by two nuclear medicine specialists. Maximum standardized uptake values (SUVmax) were determined from 14 nodal and two extranodal regions with highest uptake in each patient. Lesions were then graded with Deauville score (1-5) on FDG PET/CT and modified Krenning score (0-4) on Ga-DOTANOC PET/CT, respectively. SSTR status was analyzed from routine biopsies of lymphomatous tissue and matched to corresponding PET/CT findings.

Results: About 20/21 patients had FDG-positive lymphoma (Deauville score ≥3). Uptake of Ga-DOTANOC was regarded as positive if Krenning score was ≥2 and resulted in 13/21 (62%) patients having Ga-DOTANOC-positive lymphomas. The highest uptake of Ga-DOTANOC was seen in Hodgkin's lymphoma of nodular sclerosis subtype and in diffuse large B-cell lymphoma (SUVmax median 9.8 and 9.7, respectively). Both cases showed strong SSTR immunopositivity in tumor cells. Some patients had SSTR immunopositivity predominantly in endothelial and dendritic cells and follicular centers of lymph nodes contributing to a positive PET/CT with probably low tumor-specific uptake. SSTR and SSTR were negative in most lymphoma subtypes.

Conclusions: According to this pilot study, Ga-DOTANOC PET/CT is positive in some lymphoma subtypes which express SSTRs. These tumors present a potential risk of being misinterpreted as NETs if a representative tumor sample is not available. Lymphomas with high expression of SSTRs may be amenable to treatments targeting these receptors.